Xilio Therapeutics Presents Phase 2 Trial Data Update

Xilio Therapeutics ( (XLO) ) just unveiled an update.

On May 31, 2025, Xilio Therapeutics announced updated data from its Phase 2 clinical trial of vilastobart in combination with atezolizumab for metastatic microsatellite stable colorectal cancer. The data was presented at the 2025 American Society of Clinical Oncology Annual Meeting, highlighting the company’s ongoing efforts in advancing its tumor-activated immunotherapy pipeline. This announcement underscores Xilio’s strategic focus on leveraging its clinically validated platform to enhance its position in the oncology market.

The most recent analyst rating on (XLO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.

Spark’s Take on XLO Stock

According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.

Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.

To see Spark’s full report on XLO stock, click here.

More about Xilio Therapeutics

Xilio Therapeutics operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company is dedicated to creating tumor-activated immunotherapies to treat cancer, leveraging its proprietary platform technology to deliver differentiated molecules across various mechanisms and architectures.

Average Trading Volume: 1,135,847

Technical Sentiment Signal: Buy

Current Market Cap: $55.41M

For an in-depth examination of XLO stock, go to TipRanks’ Stock Analysis page.